检索历史 清除

目的：观察瑞舒伐他汀强化治疗对冠心病并发阵发性心房颤动的效果及对血清炎性因子的影响，为临床治疗提供借鉴。方法将176例冠心病并发阵发性心房颤动患者按随机数字表法分为观察组88例和对照组88例，对照组患者给予常规剂量的瑞舒伐他汀治疗，10 mg／d，每天1次；观察组给予瑞舒伐他汀强化治疗，20 mg／d，每天1次。治疗前、治疗后6个月进行彩色超声多普勒检查，测定左心房前后径（ LAD）、左心室射血分数（ LVEF），空腹抽血检测血清脑钠肽（ BNP）、高敏C反应蛋白（ hs-CRP）、肿瘤坏死因子（TNF-α）、白细胞介素-6（IL-6），记录治疗期间患者窦性心律维持率及栓塞事件发生情况。结果观察组和对照组治疗后LAD分别为（41．50±4．61）mm和（42．21±5．20）mm，较治疗前明显降低（t＝3．959、3．863，均P＜0.05），LVEF分别为（76±6）％和（73±5）％，较治疗前明显升高（t＝7．744和6．837，均P＜0．01），组间治疗后差异均无统计学意义（t＝1．140、0．579，均P＞0．05）。观察组和对照组治疗后BNP、hs-CRP、TNF-α、IL-6分别为（173．44±32．45） ng／L和（203．33±42．16） ng／L，（4．54±1．34） mg／L和（5．44±1．35） mg／L，（15.34±3．26）ng／L和（19.45±2．23）ng／L，（10．85±0．77）ng／L和（13．27±1．23）ng／L，均明显低于治疗前（t＝5．855和3.533、3.857和3．534、6．436和4．545、5．743和3．925，均 P ＜0．05），观察组治疗后 BNP、hs-CRP、TNF-α、IL-6水平均明显低于对照组（t＝3．546、3．214、3．176、3．414，均P＜0．05）；观察组和对照组临床总有效率、窦性心律维持率及栓塞事件发生率分别为93．18％（82／88）比79．55％（70／88），68．18％（60／88）比43．18％（38／88），2.27％（2／88）比18．18％（16／88），观察组临床总有效率、窦性心律维持率明显高于对照组（χ2＝11．965、11.144，均P＜0．01），栓塞事件发生率明显低于对照组（χ2＝12．129，P＜0．01）。结论瑞舒伐他汀强化治疗能够有效降低冠心病并发阵发性心房颤动患者血清炎性因子及BNP水平，改善左心房重构及左心房功能，临床疗效及预后均显著改善，值得临床推广使用。

Objective To observe the effect of strengthen rosuvastatin in the treatment of patients with paroxysmal atrial fibrillation in coronary artery disease and the influence on serum inflammatory factor, to provide reference for clinical treatment.Methods 176 coronary artery disease patients with paroxysmal atrial fibrillation were randomly divided into observation group and control group, 88 cases in each group.The control group was given rosuvastatin,10mg/d,qd.The observation group was given rosuvastatin,20mg/d,qd.The LAD and LVEF were detected by color-Doppler before treatment and after 6 months treatment.The fasting blood was exsanguinated for testing BNP,hs-CRP,TNF-α,IL-6.The incidence rates of sinus rhythm maintenance and embolic events were recorded. Results After treatment,the LAD of the observation group and control group were (41.50 ±4.61)mm and (42.21 ± 5.20)mm respectively,which were significantly lower than before treatment (t=3.959,3.863,all P<0.05),the LVEF were (76 ±6)% and (73 ±5)% respectively,which were significantly higher than before treatment (t =7.744,6.837,all P<0.01),there were no statistically significant differences between the two groups after treatment (t=1.140,0.579,all P>0.05).The BNP,hs-CRP,TNF-α,IL-6 levels of the observation group and control&nbsp;group after treatment were (173.44 ±32.45)ng/L and (203.33 ±42.16)ng/L,(4.54 ±1.34)mg/L and (5.44 ± 1.35)mg/L,(15.34 ±3.26) ng/L and (19.45 ±2.23) ng/L,(10.85 ±0.77) ng/L and (13.27 ±1.23) ng/L respectively,which were significantly lower than before treatment (t=5.855 and 3.533,3.857 and 3.534,6.436 and 4.545,5.743 and 3.925,all P<0.05),the BNP,hs-CRP,TNF-α,IL-6 levels of the observation group after treatment were significantly lower than the control group(t=3.546,3.214,3.176,3.414,all P<0.05).The total effective rate,sinus rhythm maintenance rate,embolic events incidence rate of the observation group and the control group were 93.18%(82/88) vs 79.55% (70/88),68.18% (60/88) vs 43.18% (38 /88),2.27%(2/88) vs 18.18%(16/88).The total effective rate,sinus rhythm maintenance rate of the observation group were significantly higher than the control group (χ2 =11.965,11.144,all P<0.01),the embolic event incidence rate was significantly lower than the control group (χ2 =12.129,P<0.01).Conclusion Strengthen rosuvastatin can effectively reduce the serum inflammatory factors and BNP,improve left atrial remodeling and left atrial function,the clinical efficacy and prognosis are significantly improved, it is worthy of clinical use in the treatment of patients with paroxysmal atrial fibrillation in coronary artery disease.